Geodon (ziprasidone) is more weight-neutral than Abilify (aripiprazole)
Both ziprasidone and aripiprazole are among the most weight-neutral antipsychotics available, but ziprasidone demonstrates slightly superior weight neutrality based on guideline evidence and clinical trial data.
Weight Profile Comparison
Ziprasidone (Geodon)
The 2017 Gastroenterology guideline explicitly identifies lurasidone and ziprasidone as the most weight-neutral options in the antipsychotic class 1. The 2015 Endocrine Society guideline reports that only 7% of patients taking ziprasidone experienced >7% weight gain from baseline, the lowest rate among five antipsychotics studied 2. In a 6-week randomized trial, ziprasidone produced minimal weight gain of only 1.0 kg 2.
Aripiprazole (Abilify)
While aripiprazole is also considered weight-favorable, guidelines describe it as having a "lower risk for weight gain" rather than being truly weight-neutral 1. A review of 34 trials in youth showed weight gain ranging from 0 to 4.4 kg with aripiprazole 2, indicating some variability and potential for weight gain in certain patients.
Key Clinical Evidence
The most compelling data comes from switching studies: patients who switched from olanzapine to ziprasidone actually lost weight and showed improvements in lipid profiles and glucose tolerance 1. A 2021 meta-analysis confirmed that switching to ziprasidone resulted in significant weight loss (-2.22 kg, 95% CI -3.84, -0.60, P=.007), while aripiprazole showed more modest weight loss (-1.96 kg) 3.
Metabolic Considerations Beyond Weight
Both medications perform well metabolically, but with different profiles:
Ziprasidone: Associated with less cholesterol increase than olanzapine, quetiapine, and risperidone 2. Demonstrated improvements in glucose tolerance when used as a switch agent 1.
Aripiprazole: Shows the lowest risk of hyperprolactinemia among all antipsychotics (relative risks: 0.11-0.21) 4 and is the least sedating option 4. A 2025 trial showed aripiprazole was associated with decreased appetite in 60.7% of patients versus increased appetite with risperidone 5.
Practical Algorithm for Selection
Choose ziprasidone when:
- Weight neutrality is the absolute priority
- Patient has pre-existing metabolic syndrome or obesity
- Switching from a high-metabolic-risk antipsychotic (olanzapine, clozapine)
- Patient needs the most metabolically benign option available
Choose aripiprazole when:
- Weight is important but hyperprolactinemia is also a concern
- Patient experiences sedation on other antipsychotics
- Partial dopamine agonism may provide additional benefit
- Patient has appetite dysregulation (aripiprazole suppresses appetite)
Important Caveats
The 2015 Endocrine Society guideline emphasizes using shared decision-making with quantitative estimates of expected weight effects 2. While both medications are excellent choices for metabolic concerns, neither is completely weight-neutral in all patients—individual responses vary.
A critical consideration: the 2026 SNAP trial found that while ziprasidone had favorable metabolic effects, it showed higher all-cause discontinuation rates than some other antipsychotics 4. This suggests that while ziprasidone is more weight-neutral, treatment adherence and overall efficacy must be weighed against metabolic benefits.
Bottom line: If weight neutrality is your primary concern and the patient can tolerate the medication, ziprasidone edges out aripiprazole based on guideline recommendations and clinical trial data showing the lowest weight gain potential among all antipsychotics 1.